1. A summary of the changes follows. In 2000, Decree 57-2000 authorized brand-name companies to register their products for data exclusivity for fifteen years. A list of twenty-two data-protected drugs was created. In 2002, Decree 76-2002 eliminated data exclusivity for any time period. In 2003, Decree 9-2003 repealed Decree 76-2002 and implemented five years of data exclusivity. The U.S. Department of Commerce's Special 301 Watchlist is a prelude to possible trade sanctions. In 2003 the Special 301 Watchlist noted unfavorably Decree 76-2002 and encouraged the ongoing implementation of Decree 9-2003. Office of the U.S. Trade Representative, 2003 Special 301 Report (Washington: Executive Office of the President, 2003), 22. Decree 9-2003 also stated that the protected data “must require considerable effort to produce,” an attempt to limit the frivolous listing of medicines. In 2004, Decree 34-04 repealed Decree 9-2003, again eliminating data exclusivity. As CAFTA was being negotiated in 2005, Decree 30-2005 repealed Decree 34-04 and reinstated a five-year period for data exclusivity. It states that trade agreements will prevail over this law in the event of conflicts.